Buradasınız

Anasayfa » Content

Eski Hastalıklar İçin Yeni Fırsatlar: Akuaretikler (Vazopresin Reseptör Antagonistleri)

New Options for Old Diseases: Aquaretics (Vasopressin Receptor Antagonists)

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2011
DOI: 
DOI 10.5262/tndt.2011.1001.03

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
There are multiple receptors for vasopressin (ADH) named the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors principally cause vasoconstriction and mediate adrenocorticotropin release, respectively. Some oral formulations of vasopressin receptor antogonists - tolvaptan, satavaptan, and lixivaptan — are selective for the V2 receptor, while an intravenous agent, conivaptan, blocks both the V2 and V1a receptors and is approved for the management of patients with euvolemic hyponatremia (mostly due to SIADH) and hypervolemic hyponatremia. The vasopressin receptor antagonists produce a selective water diuresis without affecting sodium and potassium excretion. The ensuing loss of free water will tend to correct the hyponatremia in patients with SIADH. Elevated levels of vasopressin may contribute to the increase in systemic vascular resistance in heart failure via stimulation of the V1a receptor, which is found on vascular smooth muscle cells, and also promote renal water retention via the V2 receptor, leading to the development of hyponatremia. At present, conivaptan is the only vasopressin receptor antagonist approved for use. In patients with heart failure, conivaptan both raises the serum sodium concentration and, via blockade of the V1a receptors, diminishes afterload, possibly improving systemic hemodynamics. V2 receptor antagonists (aquaretics) have a critical role in the management of the hyponatremia of SIADH, heart failure, ascites of hepatic failure and they may also diminish the cystogenesis in the early stages of polycystic kidney disease.
Bookmark/Search this post with
Abstract (Original Language): 
Vazopresinin (ADH) V1a,V1b ve V2 olarak çok sayıda reseptörleri vardır. V2 reseptörleri antidiüretik yanıttan sorumlu iken V1a ve V1b reseptörleride sırasıyla vazokonstrüksiyona neden olur ve adrenokortikotropin salınımını sağlar. Vazopresin oral reseptör antagonistlerinin bazıları – tolvaptan, satavaptan ve lixivaptan- V2 reseptörleri için seçiciyken intravenöz ajan conivaptan da hem V2 hemde V1a reseptörlerini bloke eder. Vazopresin reseptör antagonistleri sodyum ve potasyum atılımını etkilemeden seçici su diürezi yapar. Uygunsuz ADH sendromundaki hiponatremiyi yalnız serbest su kaybı ile düzeltir. Kalp yetmezliğinde vasküler düz kas hücrelerinde bulunan V1a reseptor uyarısı ile artan vasopresin düzeyleri sistemik vasküler rezistansı arttırır ve V2 reseptörleri renal su tutulmasına neden olarak hiponatremiye neden olur. Conivaptan halen kullanım onayı almış tek vazopresin reseptör antagonistidir (akuaretik) . Kalp yetmezliği olan hastalarda conivaptan serum sodyum konsantrasyonunu V1a reseptörlerini bloke ederek arttırır, ve muhtemelen sistemik hemodinamiyi düzelterek ard yükü azaltır. V2 reseptör antagonistleri uygunsuz ADH sendromunda, kalp yetmezliğinde, karaciğer yetmezliği asitinin tedavisinde kritik rol oynayabilir ve polikistik böbrek hastalığının erken aşamalarında kistogeneze engel olabilir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_20_pp_14-18.pdf
  • 1
14-18
  • Turkish

REFERENCES

References: 

1. Arai Y, Fujimori A, Sasamata M, Miyata K: New topics in vasopressin
receptors and approach to novel drugs: Research and development
of conivaptan hydrochloride (YM087), a drug for the treatment of
hyponatremia. J Pharmacol Sci 2009; 109(1): 53-59
2. Arai Y, Fujimori A, Sudoh K, Sasamata M: Vasopressin receptor
antagonists: Potential indications and clinical results. Curr Opin
Pharmacol 2007; 7(2): 124-129
3. Filippatos G, Parissis JT: Vasopressin antagonists for the treatment
of acute decompensated heart failure: When, for whom, for how
long, and on what standard therapy? Card Fail 2008; 14(8):
648-650
4. Baylis PH: The syndrome of inappropriate antidiuretic hormone
secretion. Int J Biochem Cell Biol 2003; 35(11): 1495-1499
5. Martín-Llahí M, Guevara M, Ginès P: Hyponatremia in cirrhosis:
Clinical features and management. Gastroenterol Clin Biol 2006;
30(10): 1144-1151
6. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu
D; HypoCAT Study Investigators: Effects of satavaptan, a selective
vasopressin V(2) receptor antagonist, on ascites and serum sodium
in cirrhosis with hyponatremia: A randomized trial. Hepatology.
2008; 48(1): 204-213
7. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA,
Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi
L, for the International Working Group on Acute Heart Failure
Syndromes: Acute heart failure syndromes: Current state and frame
work for future research: Circulation 2005; 112: 3958-3968
8. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam
U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M,
Ouyang J, Orlandi C, for the Acute and Chronic Therapeutic Impact
of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in
CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist,
in patients hospitalized with worsening heart failure: A randomized
controlled trial: JAMA 2004; 291: 1963-1971
9. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni
AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer
C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure
Study with Tolvaptan (EVEREST) Investigators: Effects of oral
tolvaptan in patients hospitalized for worsening heart failure: The
EVEREST Out Come Trial: JAMA 2007; 297: 1391-1431
10. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin
directly regulates cyst growth in polycystic kidney disease. J Am
Soc Nephrol 2008; 19(1): 102-108

Thank you for copying data from http://www.arastirmax.com